Home › Compare › CDAK vs FCPT

CDAK vs FCPT: Dividend Comparison 2026

CDAK yields 3508.77% · FCPT yields 6.05%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CDAK wins by $2034141393542.03M in total portfolio value
10 years
CDAK
CDAK
● Live price
3508.77%
Share price
$0.06
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2034141393542.08M
Annual income
$1,926,153,862,282,748,700.00
Full CDAK calculator →
FCPT
FCPT
● Live price
6.05%
Share price
$23.65
Annual div
$1.43
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.1K
Annual income
$5,775.28
Full FCPT calculator →

Portfolio growth — CDAK vs FCPT

📍 CDAK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCDAKFCPT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CDAK + FCPT cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
CDAK pays
FCPT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CDAK
Annual income on $10K today (after 15% tax)
$298,245.61/yr
After 10yr DRIP, annual income (after tax)
$1,637,230,782,940,336,400.00/yr
FCPT
Annual income on $10K today (after 15% tax)
$514.49/yr
After 10yr DRIP, annual income (after tax)
$4,908.99/yr
At 15% tax rate, CDAK beats the other by $1,637,230,782,940,331,500.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CDAK + FCPT for your $10,000?

CDAK: 50%FCPT: 50%
100% FCPT50/50100% CDAK
Portfolio after 10yr
$1017070696771.07M
Annual income
$963,076,931,141,377,300.00/yr
Blended yield
94.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on FCPT right now

CDAK
No analyst data
Altman Z
-4.4
Piotroski
2/9
FCPT
Analyst Ratings
5
Buy
10
Hold
Consensus: Hold
Price Target
$27.00
+14.2% upside vs current
Range: $25.00 — $29.00
Altman Z
1.4
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CDAK buys
0
FCPT buys
0
No recent congressional trades found for CDAK or FCPT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCDAKFCPT
Forward yield3508.77% ✓6.05%
Annual dividend / share$2.00 ✓$1.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$2034141393542.08M ✓$49.1K
Annual income after 10y$1,926,153,862,282,748,700.00 ✓$5,775.28
Total dividends collected$2026733119198.63M ✓$24.1K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CDAK vs FCPT ($10,000, DRIP)

YearCDAK PortfolioCDAK Income/yrFCPT PortfolioFCPT Income/yrGap
1← crossover$361,577$350,877.19$11,401$700.92+$350.2K → CDAK
2$12,243,821$11,856,933.69$13,064$864.84+$12.23M → CDAK
3$388,336,948$375,236,059.53$15,051$1,072.48+$388.32M → CDAK
4$11,538,279,357$11,122,758,822.00$17,442$1,337.22+$11538.26M → CDAK
5$321,205,540,543$308,859,581,631.20$20,340$1,677.08+$321205.52M → CDAK
6$8,379,307,864,544$8,035,617,936,162.96$23,880$2,116.57+$8379307.84M → CDAK
7$204,877,671,222,196$195,911,811,807,134.25$28,241$2,689.36+$204877671.19M → CDAK
8$4,695,974,086,156,479$4,476,754,977,948,728.50$33,660$3,442.07+$4695974086.12M → CDAK
9$100,922,926,410,592,910$95,898,234,138,405,470.00$40,456$4,439.95+$100922926410.55M → CDAK
10$2,034,141,393,542,082,800$1,926,153,862,282,748,700.00$49,063$5,775.28+$2034141393542.03M → CDAK

CDAK vs FCPT: Complete Analysis 2026

CDAK — Stock

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full CDAK Calculator →

FCPT — REIT

FCPT, headquartered in Mill Valley, CA, is a real estate investment trust primarily engaged in the acquisition and leasing of restaurant properties. The Company seeks to grow its portfolio by acquiring additional real estate to lease, on a net basis, for use in the restaurant and retail industries.

Full FCPT Calculator →
📬

Get this CDAK vs FCPT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CDAK vs SCHDCDAK vs JEPICDAK vs OCDAK vs KOCDAK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.